ArticleFEBS letters2012
Delivery of Bordetella pertussis adenylate cyclase toxin to target cells via outer membrane vesicles.
Article in FEBS letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?Microorganisms · 2024Article
- Prokaryotic microvesicles Ortholog of eukaryotic extracellular vesicles in biomedical fields.Cell communication and signaling : CCS · 2024Review
- Review
- Involvement of Bacterial Extracellular Membrane Nanovesicles in Infectious Diseases and Their Application in Medicine.Pharmaceutics · 2022Review
- Bacterial Nucleotidyl Cyclases Activated by Calmodulin or Actin in Host Cells: Enzyme Specificities and Cytotoxicity Mechanisms Identified to Date.International journal of molecular sciences · 2022Review
- Review
- Extracellular cAMP: The Past and Visiting the Future in cAMP-Enriched Extracellular Vesicles.Advanced biology · 2021Article
- Size Exclusion Chromatography to Analyze Bacterial Outer Membrane Vesicle Heterogeneity.Journal of visualized experiments : JoVE · 2021Article
- Engineered Remolding and Application of Bacterial Membrane Vesicles.Frontiers in microbiology · 2021Review
- Pathogenesis Mediated by Bacterial Membrane Vesicles.Sub-cellular biochemistry · 2021Article
- Bacterial Outer Membrane Vesicles as Antibiotic Delivery Vehicles.Frontiers in immunology · 2021Review
- Review
- Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.Molecular oral microbiology · 2020Review
- Impact of Bacterial Toxins in the Lungs.Toxins · 2020Review
- Article
- Bordetella pertussis Adenylate Cyclase Toxin Disrupts Functional Integrity of Bronchial Epithelial Layers.Infection and immunity · 2018Article
- Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis.Infection and immunity · 2017Article
- Strategies and new developments to control pertussis, an actual health problem.Pathogens and disease · 2015Review
- Outer membrane vesicles as platform vaccine technology.Biotechnology journal · 2015Review
- Membrane vesicles of Clostridium perfringens type A strains induce innate and adaptive immunity.International journal of medical microbiology : IJMM · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Bordetella pertussis adenylate cyclase toxin (ACT) intoxicates cells by producing intracellular cAMP. B. pertussis outer membrane vesicles (OMV) contain ACT on their surface (OMV-ACT), but the properties of OMV-ACT were previously unknown. We found that B. pertussis in the lung from a fatal pertussis case contains OMV, suggesting an involvement in pathogenesis. OMV-ACT and ACT intoxicate cells with and without the toxin's receptor CD11b/CD18. Intoxication by ACT is blocked by antitoxin and anti-CD11b antibodies, but not by cytochalasin-D; in contrast, OMV-ACT is unaffected by either antibody and blocked by cytochalasin-D. Thus OMV-ACT can deliver ACT by processes distinct from those of ACT alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.